Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells

Area of Science:

• Immunology
• Cancer Biology
• Metabolomics

Background:

• The tumor microenvironment's immunosuppressive nature hinders effective cancer immunotherapy.
• Tumor metabolites, including 5'-deoxy-5'-methylthioadenosine (MTA), significantly shape this microenvironment.
• Elevated intratumoral MTA levels are linked to the absence of the methylthioadenosine phosphorylase (MTAP) enzyme in various cancers.

Purpose of the Study:

• To investigate the impact of MTA on T cell function and identify its underlying molecular mechanisms.
• To explore the role of MTA in tumor immune evasion strategies.
• To assess the therapeutic potential of targeting MTA-mediated immunosuppression.

Main Methods:

• In vitro assays assessing T cell proliferation, activation, differentiation, and effector functions upon MTA exposure.
• Analysis of signaling pathways, including Akt and p38, in MTA-treated T cells.
• Protein methylation analysis in T cells.
• Co-culture experiments using MTAP-deficient tumor cells, MTAP-transfected tumor cells, and human T cells.

Main Results:

• MTA suppresses T cell proliferation, activation, differentiation, and effector functions without inducing cell death.
• MTA exhibits cytotoxic effects on highly activated T cells.
• The Akt signaling pathway is a key target of MTA, while p38 remains unaffected.
• MTA interferes with protein methylation in T cells, contributing to immunosuppression.
• T cells stimulated with MTAP-transfected tumor cells show enhanced proliferative capacity compared to those stimulated with mock-transfected cells.

Conclusions:

• MTA is a critical tumor metabolite that actively suppresses T cell-mediated anti-tumor immunity.
• Interference with protein methylation is a novel mechanism by which MTA exerts immunosuppressive effects.
• Restoring MTAP expression in tumors can counteract MTA-induced immunosuppression and enhance T cell responses.
• Targeting MTA or restoring MTAP represents a promising strategy for overcoming immune evasion in cancer therapy.